Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Schuh · SciRah

Researcher profile · Semantic Scholar

A. Schuh

Share profile

A. Schuh — researcher profile on SciRah

h-index: 45
Works: 300
Citations: 17K

Most-cited papers

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
P. Montesinos, C. Récher, S. Vives, E. Zarzycka +12 more
2022New England Journal of Medicine402 citations Open access
Semantic Scholar
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
K. Pratz, B. Jonas, V. Pullarkat, C. Récher +16 more
2021Journal of Clinical Oncology156 citations Open access
Semantic Scholar
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
C. Dinardo, A. Schuh, E. Stein, P. Montesinos +13 more
2021The Lancet Oncology156 citations Open access
Semantic Scholar
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
C. Dinardo, A. Stein, E. Stein, A. Fathi +24 more
2020Journal of Clinical Oncology145 citations Open access
Semantic Scholar
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
D. Pollyea, K. Pratz, A. Wei, V. Pullarkat +9 more
2022Clinical Cancer Research130 citations Open access
Semantic Scholar
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
S. de Botton, P. Montesinos, A. Schuh, C. Papayannidis +23 more
2022Blood114 citations Open access
Semantic Scholar
ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
H. Döhner, K. Pratz, C. Dinardo, B. Jonas +11 more
2022Blood76 citations Open access
Semantic Scholar
Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status.
G. Roboz, F. Ravandi, A. Wei, H. Dombret +12 more
2022Blood62 citations Open access
Semantic Scholar
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
A. Zeidan, P. Boddu, M. Patnaik, J. Bewersdorf +48 more
2020The Lancet Haematology59 citations Open access
Semantic Scholar
Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations
O. Calvillo-Arguelles, Alice Schoffel, Jose-Mario Capo-Chichi, H. Abdel-Qadir +9 more
2022JACC CardioOncology56 citations Open access
Semantic Scholar
Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia
Robert Puckrin, E. Atenafu, J. Claudio, Steven M. Chan +12 more
2020Haematologica44 citations Open access
Semantic Scholar
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
K. Pratz, P. Panayiotidis, C. Récher, Xu-Dong Wei +22 more
2022Blood Cancer Journal32 citations Open access
Semantic Scholar
Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).
C. Dinardo, A. Schuh, E. Stein, P. Montesinos +12 more
202032 citations
Semantic Scholar
TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation
Davidson Zhao, Mojgan Zarif, Qiang-Hua Zhou, Jose-Mario Capo-Chichi +5 more
2023Cancers27 citations Open access
Semantic Scholar
Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase‐based therapy
H. Sibai, Rui-Qi Chen, Xing Liu, Umberto Falcone +14 more
2020British Journal of Haematology24 citations Open access
Semantic Scholar
The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)
A. Zeidan, J. Esteve, A. Giagounidis, Hee-Je Kim +16 more
202023 citations Open access
Semantic Scholar
Enasidenib in Combination with Venetoclax in IDH2-Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial
Steven M. Chan, Charina Cameron, S. Cathelin, V. Gupta +9 more
2021Blood20 citations
Semantic Scholar
Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.
S. de Botton, P. Montesinos, Susana Vives Polo, E. Zarzycka +11 more
2023Journal of Clinical Oncology19 citations
Semantic Scholar
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Kenny Tang, A. Schuh, K. Yee
2021Current Oncology Reports19 citations
Semantic Scholar
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents
D. Pollyea, K. Pratz, A. Wei, V. Pullarkat +9 more
2021Blood19 citations
Semantic Scholar
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms
T. Murphy, J. Mason, Brian Leber, M. R. Bray +16 more
2023Leukemia17 citations Open access
Semantic Scholar
NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
Davidson Zhao, Mojgan Zarif, Entsar Eladl, Jose-Mario Capo-Chichi +6 more
2022Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis17 citations
Semantic Scholar
Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
Davidson Zhao, Entsar Eladl, Mojgan Zarif, Jose-Mario Capo-Chichi +4 more
2022Cancer Medicine17 citations Open access
Semantic Scholar
AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A
C. Dinardo, B. Jonas, V. Pullarkat, M. Thirman +28 more
202017 citations
Semantic Scholar
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
R. Shallis, Naval G. Daver, J. Altman, R. Komrokji +37 more
2023The Lancet Haematology16 citations
Semantic Scholar
AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML).
A. Zeidan, J. Westermann, T. Kovacsovics, S. Assouline +10 more
2022Clinical Lymphoma, Myeloma & Leukemia16 citations
Semantic Scholar
Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
Georgina S. Daher-Reyes, TaeHyung Kim, I. Novitzky-Basso, Kyuoung Ha Kim +25 more
2021Bone Marrow Transplantation16 citations
Semantic Scholar
CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial
G. Roboz, F. Ravandi, A. Wei, H. Dombret +13 more
202016 citations
Semantic Scholar
Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN
M. Davidson, James A. Kennedy, Jose-Mario Capo-Chichi, Yuliang Shi +15 more
2024Blood Advances14 citations Open access
Semantic Scholar
Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2-Mutated Relapsed/Refractory Myeloid Malignancies
Guillaume Richard-Carpentier, Gopila Gupta, Charina Cameron, S. Cathelin +14 more
2023Blood14 citations
Semantic Scholar
Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario
A. Tierens, T. Stockley, Clinton J. V. Campbell, Jill Fulcher +5 more
2021Current Oncology14 citations Open access
Semantic Scholar
The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus
Julie Bergeron, Jose-Mario Capo-Chichi, Hubert Tsui, Etienne Mahe +4 more
2023Current Oncology11 citations Open access
Semantic Scholar
P582: FIRST RESULTS OF A PHASE II STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
A. M. Zeidan, J. Westermann, T. Kovacsovics, S. Assouline +10 more
2022HemaSphere11 citations Open access
Semantic Scholar
Outcomes for Patients with Late-Stage Mutant-IDH2 (m IDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial
C. Dinardo, P. Montesinos, A. Schuh, C. Papayannidis +8 more
2021Blood10 citations
Semantic Scholar
Oral Abstract: AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation
H. Döhner, P. Montesinos, S. Polo, E. Zarzycka +14 more
2022Clinical Lymphoma, Myeloma & Leukemia9 citations
Semantic Scholar
Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.
K. Pratz, B. Jonas, V. Pullarkat, C. Récher +16 more
20219 citations
Semantic Scholar
Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation
J. Lucero, Muhned Alhumaid, I. Novitzky-Basso, Jose-Mario Capo-Chichi +11 more
2024Annals of Hematology8 citations
Semantic Scholar
CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial
A. Wei, G. Roboz, H. Dombret, H. Döhner +11 more
20208 citations Open access
Semantic Scholar
Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.
V. Pullarkat, K. Pratz, H. Döhner, C. Récher +16 more
2021Journal of Clinical Oncology7 citations
Semantic Scholar
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation
H. Iland, N. Russell, R. Dillon, A. Schuh +21 more
2022Blood Advances6 citations Open access
Semantic Scholar
Timely diagnosis and treatment of acute promyelocytic leukemia should be available to all
A. Schuh
2021Haematologica6 citations Open access
Semantic Scholar
Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia
T. Murphy, Jinfeng Zou, A. Arruda, Ting-Ting Wang +14 more
2023Haematologica5 citations Open access
Semantic Scholar
Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase
M. Perusini, C. Andrews, E. Atenafu, Vikas Gupta +11 more
2024Hematology4 citations Open access
Semantic Scholar
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia.
I. Aldoss, G. Roboz, R. Bassan, N. Boissel +10 more
2024The Lancet Haematology4 citations
Semantic Scholar
Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia
A. Tierens, E. Kagotho, Satoru Shinriki, A. Seto +11 more
2023Frontiers in Oncology4 citations Open access
Semantic Scholar
AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.
Davidson Zhao, Qiang-Hua Zhou, Mojgan Zarif, Entsar Eladl +7 more
2023Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis4 citations
Semantic Scholar
Abstract CT026: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies
C. Dinardo, P. Montesinos, L. Benajiba, A. Triguero +38 more
2023Cancer Research4 citations
Semantic Scholar
Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis
K. Guinan, K. Mathurin, Yung-Han Au, A. Schuh +3 more
2022Current Oncology4 citations Open access
Semantic Scholar
Safety of re‐challenging adults with acute lymphoblastic leukemia with PEG‐asparaginase‐induced severe hypertriglyceridemia when treated with a pediatric‐inspired regimen
Ibrahim Al Nabhani, C. Andrews, J. Sibai, E. Atenafu +8 more
2022eJHaem4 citations Open access
Semantic Scholar
Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
D. DeAngelo, A. Schuh, Brian A. Jonas, Pamela S. Becker +21 more
2024Blood3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Dinardo×16
Invite
C. Dinardo — researcher profile on SciRah
M. Minden×16
Invite
M. Minden — researcher profile on SciRah
H. Döhner×15
Invite
H. Döhner — researcher profile on SciRah
A. Wei×14
Invite
A. Wei — researcher profile on SciRah

×12

Invite

P. Montesinos — researcher profile on SciRah

Invite

C. Récher — researcher profile on SciRah

Invite

H. Sibai — researcher profile on SciRah

Invite

Dawn Maze — researcher profile on SciRah

Invite

K. Pratz — researcher profile on SciRah

Jose-Mario Capo-Chichi×10

Invite

Jose-Mario Capo-Chichi — researcher profile on SciRah

A. Schimmer×10

Invite

A. Schimmer — researcher profile on SciRah

S. de Botton×9

Invite

S. de Botton — researcher profile on SciRah